• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用非模型方法对四种凝血因子VIII浓缩物进行动力学评估。

Kinetic evaluation of four Factor VIII concentrates by model-independent methods.

作者信息

Matucci M, Messori A, Donati-Cori G, Longo G, Vannini S, Morfini M, Tendi E, Rossi-Ferrini P L

出版信息

Scand J Haematol. 1985 Jan;34(1):22-8. doi: 10.1111/j.1600-0609.1985.tb00739.x.

DOI:10.1111/j.1600-0609.1985.tb00739.x
PMID:3918340
Abstract

Single-dose kinetics of 4 Factor VIII concentrates (Kryobulin, Hemofil T, Koate, cryoprecipitate) were studied in 41 patients with haemophilia-A. Model-independent methods were adopted for calculating the kinetic parameters (area under the curve, clearance, area under the moment curve, mean residence time, volume of distribution at steady-state). No substantial difference was observed in the kinetic characteristics of the 4 Factor VIII concentrates. A considerable interindividual variability of the calculated kinetic parameters was demonstrated for all concentrates. Our findings support the need to individualize Factor VIII dosage.

摘要

对41例甲型血友病患者研究了4种凝血因子VIII浓缩剂(冷沉淀球蛋白、海莫费尔T、科亚特、冷沉淀)的单剂量动力学。采用非模型方法计算动力学参数(曲线下面积、清除率、矩曲线下面积、平均驻留时间、稳态分布容积)。4种凝血因子VIII浓缩剂的动力学特征未观察到实质性差异。所有浓缩剂计算出的动力学参数均显示出相当大的个体间变异性。我们的研究结果支持凝血因子VIII剂量个体化的必要性。

相似文献

1
Kinetic evaluation of four Factor VIII concentrates by model-independent methods.采用非模型方法对四种凝血因子VIII浓缩物进行动力学评估。
Scand J Haematol. 1985 Jan;34(1):22-8. doi: 10.1111/j.1600-0609.1985.tb00739.x.
2
Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods.用非模型方法估算新型热处理凝血因子 VIII 浓缩剂的药代动力学
Thromb Res. 1986 May 15;42(4):471-6. doi: 10.1016/0049-3848(86)90210-0.
3
Cryoprecipitate and Factor VIII commercial concentrates: in vitro characteristics and in vivo compartmental analysis.
Ric Clin Lab. 1984 Oct-Dec;14(4):681-91. doi: 10.1007/BF02906309.
4
Low recovery in vivo of highly purified factor VIII in patients with hemophilia.血友病患者体内高纯度凝血因子VIII的回收率较低。
J Pediatr. 1992 Nov;121(5 Pt 1):814-8. doi: 10.1016/s0022-3476(05)81921-3.
5
Individualization of Factor VIII dosage.凝血因子 VIII 剂量的个体化
J Clin Hosp Pharm. 1984 Jun;9(2):95-103. doi: 10.1111/j.1365-2710.1984.tb01065.x.
6
In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.单克隆抗体纯化的凝血因子 VIII 浓缩物的体内回收率和存活率。
Thromb Haemost. 1991 Dec 2;66(6):730-3.
7
Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.三种单克隆凝血因子VIII浓缩剂的药代动力学比较评估
Thromb Res. 1991 Feb 1;61(3):285-90. doi: 10.1016/0049-3848(91)90105-6.
8
Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients.两种药代动力学技术在血友病患者中个体化因子VIII剂量的比较。
Haematologica. 1985 Sep-Oct;70(5):454-6.
9
Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A.在甲型血友病患者中,经溶剂/去污剂处理并额外进行80摄氏度末端干热处理的抗血友病因子的安全性和有效性。
Haemophilia. 2000 May;6(3):140-9. doi: 10.1046/j.1365-2516.2000.00407.x.
10
Hemofil and other factor VIII concentrates.血液滤过液及其他凝血因子VIII浓缩剂。
Med Lett Drugs Ther. 1969 Nov 14;11(23):96.

引用本文的文献

1
Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.通过二室模型研究重组人凝血因子VIII的药代动力学,结果显示A型血友病患者呈现双相衰减、较长的平均驻留时间和β半衰期。
J Clin Med. 2024 Aug 23;13(17):4986. doi: 10.3390/jcm13174986.
2
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.一种在重度血友病 A 患者中使用 ADVATE myPKFiT 剂量工具生成药代动力学特征的实用单诊次方案。
Thromb Haemost. 2021 Oct;121(10):1326-1336. doi: 10.1055/a-1376-0970. Epub 2021 Apr 14.
3
Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors.
生存曲线分析:考虑长期存活者存在情况的统计方法
Front Oncol. 2019 Jun 4;9:453. doi: 10.3389/fonc.2019.00453. eCollection 2019.
4
The History of Clotting Factor Concentrates Pharmacokinetics.凝血因子浓缩物药代动力学的历史
J Clin Med. 2017 Mar 20;6(3):35. doi: 10.3390/jcm6030035.
5
Pediatric Dosing and Body Size in Biotherapeutics.生物治疗药物中的儿科剂量与身体尺寸
Pharmaceutics. 2010 Dec 16;2(4):389-418. doi: 10.3390/pharmaceutics2040389.
6
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.VIII 因子的异速生长与新一代治疗性蛋白的信息缩放。
J Pharm Sci. 2013 Jul;102(7):2380-94. doi: 10.1002/jps.23566. Epub 2013 Apr 25.
7
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.儿童和成人血浆游离型和白蛋白结合型重组因子 VIII 的比较药代动力学:采血方案对观察到的与年龄相关差异的影响及其对剂量调整的意义。
J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x.
8
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.3至74岁年龄范围内凝血因子VIII的药代动力学及剂量需求:一项基于50例长期接受血友病A预防性治疗患者的群体分析。
Eur J Clin Pharmacol. 2009 Oct;65(10):989-98. doi: 10.1007/s00228-009-0676-x. Epub 2009 Jun 26.
9
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.凝血因子的药代动力学:对血友病患者的临床意义
Clin Pharmacokinet. 2001;40(11):815-32. doi: 10.2165/00003088-200140110-00003.
10
Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs.
Eur J Clin Pharmacol. 1988;35(6):663-8. doi: 10.1007/BF00637604.